Prognostic value of claudin 18.2 expression in gastric adenocarcinoma.

ABSTRACT:

Background

Claudin 18.2 (CLDN18.2) is a cell surface protein expressed by gastric cancer cells. The monoclonal antibody zolbetuximab binds CLDN18.2-positive cancer cells and causes cancer cell death. A few studies researched the prognostic effect of CLDN18.2 expression in metastatic gastric adenocarcinoma.

Aim

To identify the prognostic value of CLDN18.2 expression in patients with metastatic gastric adenocarcinoma.

Methods

This study was conducted with 65 patients over the age of 18 who were diagnosed with metastatic gastric adenocarcinoma. We investigated the effect of CLDN18.2 expression on clinicopathological characteristics (age, sex, histological grade, Lauren classification, family history, metastatic site, HER2 expression) and prognosis for patients with metas

SUBMITTER: Kayikcioglu E 

PROVIDER: S-EPMC9994048 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature